當前位置:BPS Bioscience Inc.>>Immunotherapy Cell Lines>> 71273ADCP Bioassay Effector Cell FcγRIIa (H Variant)/ NFAT Luciferase Reporter Jurkat Cell Line
ADCP Bioassay Effector Cell FcγRIIa (H Variant)/NFAT Reporter Jurkat Cells are Jurkat T cells engineered to express firefly luciferase under the control of NFAT response elements, and human FcγRIIa, H variant. This cell line was functionally validated in a ADCP (antibody-dependent cell-mediated phagocytosis) assay.
Figure 1: Illustration of the mechanism of action of ADCP Bioassay Effector Cell FcγRIIa (H Variant)/NFAT Luciferase Reporter Jurkat Cell Line.
ADCP Bioassay Effector Cell FcγRIIa (H Variant)/NFAT Luciferase Reporter Jurkat cells are used as effector cells. The effector cells are co-cultured in the presence of target cells and an antibody of interest. The antibody binds to the target antigen on the target cell whereas its Fc portion binds to FcγRIIa on the cell surface of the effector cell, cross-linking the effector and target cells. Engagement of FcγRIIa leads to the activation of the NFAT pathway in the effector cells. Luciferase activity is proportional to the activation of the ADCP cascade.
Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.
請輸入賬號
請輸入密碼
請輸驗證碼
以上信息由企業自行提供,信息內容的真實性、準確性和合法性由相關企業負責,化工儀器網對此不承擔任何保證責任。
溫馨提示:為規避購買風險,建議您在購買產品前務必確認供應商資質及產品質量。